COVID-19 Treatments

COVID-19 Treatments

To Submit a Self-Referral for COVID-19 EUA Monoclonal Antibody Therapy:

  1. Click the Referral Link below to fill out the form
  2. Fax COVID positive lab results to (510) 969-5840 (if you do not have access to a fax machine, you must bring a copy of the COVID-19 positive lab result to the appointment)
  3. Upon receipt of the online referral form, Total Infusion will contact you to coordinate treatment (patients are contacted within 4 business hours and offered a same or next business day appointment)

Patient Self-Referral Link

Did You Recently Test Positive for COVID-19?

You may be eligible for treatment

MONOCLONAL ANTIBODIES FOR HIGH-RISK COVID-19 POSITIVE PATIENTS

If you’ve tested positive for COVID-19, one of the first questions you may have is, What can I do to reduce the risk of getting sicker? The good news is, there are treatments that may reduce that risk. Depending on your age, health history, and how long you’ve had symptoms of COVID-19, you may qualify for a promising form of treatment for the disease. It’s called monoclonal antibody (mAb) treatment.

Some early evidence suggests that mAb treatment can reduce the amount of the SARS-CoV-2 virus (the virus that causes COVID-19) in a person’s system. This amount is known as viral load. Having a lower viral load means you may have milder symptoms thereby decreasing the likelihood of you needing to stay in the hospital.

mAb treatment may help people who:

  • Have a positive COVID-19 test, and had symptoms for 10 days or less
  • Are at high risk of getting more serious symptoms

Source Cited: combatcovid.hhs.gov

What Are Monoclonal Antibody COVID-19 Treatments?

Monoclonal antibodies are like your body’s own antibodies as they help your immune system quickly destroy the COVID-19 virus before it harms you or causes hospitalization. Fortunately, the U.S. Food and Drug Administration has authorized monoclonal antibody treatment for emergency use for eligible patients.

If you test positive for COVID-19 or have symptoms, talk to a healthcare provider right away. Monoclonal antibody treatment must be given as soon as possible within 7 days of getting a symptom. These treatments are of little to no cost to you and are given through a one-time IV infusion.

Treatment Criteria
AT LEAST 12 YEARS OF AGE AND 88 POUNDS
AT LEAST ONE HIGH RISK CONDITION
ACTIVE INFECTION
COVID-19 Positive
(PCR or Rapid Antigen Test)
Onset of Mild to Moderate
Symptoms within 7 DAYS

Treatment Criteria

AT LEAST 12 YEARS OF AGE AND 88 POUNDS

AT LEAST ONE HIGH RISK CONDITION

ACTIVE INFECTION

COVID-19 Positive
(PCR or Rapid Antigen Test)

Onset of Mild to Moderate
Symptoms within 7 DAYS

HIGH RISK CONDITIONS
Other medical conditions or factors may also place individual patients at high risk for progression to severe COVID-19; authorization of REGEN-COV under the EUA is not limited to the medical conditions or factors listed below
Age > 65 of age Cardiovascular Disease/HTN
Overweight/Obesity (BMI>25) Sickle Cell Disease
Pregnancy/Postpartum (42 days) Neurodevelopmental Disorders
Chronic Kidney Disease Medical Related Technological Dependence
Diabetes Race/Ethnicity
Immunosuppressive Disease/Treatment Other Medical Conditions

HIGH RISK CONDITIONS
Other medical conditions or factors may also place individual patients at high risk for progression to severe COVID-19; authorization of REGEN-COV under the EUA is not limited to the medical conditions or factors listed below

Age > 65 of age

Cardiovascular Disease/HTN

Overweight/Obesity (BMI>25)

Sickle Cell Disease

Pregnancy/Postpartum (42 days)

Neurodevelopmental Disorders

Chronic Kidney Disease

Medical Related Technological Dependence

Diabetes

Race/Ethnicity

Immunosuppressive Disease/Treatment

Other Medical Conditions

PATIENTS ARE NOT ELIGIBLE FOR TREATMENT IF:
Hospitalized due to COVID-19
Require oxygen therapy due to COVID-19
Require an increase in baseline oxygen flow rate due to COVID-19 for those on chronic oxygen therapy due to underlying non-COVID-19 related health issue

PATIENTS ARE NOT ELIGIBLE FOR TREATMENT IF:

Hospitalized due to COVID-19

Require oxygen therapy due to COVID-19

Require an increase in baseline oxygen flow rate due to COVID-19 for those on chronic oxygen therapy due to underlying non-COVID-19 related health issue

FACT SHEET:
Important Information About Bebtelovimab

Bebtelovimab is an investigational medicine used to treat mild-to-moderate symptoms of COVID-19 in adults and children (12 years of age and older weighing at least 88 pounds [40 kg]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk of progression to severe COVID-19, including hospitalization or death. Bebtelovimab is investigational because it is still being studied. There is limited information about the safety and effectiveness of using Bebtelovimab to treat people with mild-to moderate COVID-19.

LIMITATIONS OF AUTHORIZED USE:
  • Bebtelovimab is not authorized for use in patients:
    • who are hospitalized due to COVID-19, OR
    • who require oxygen therapy due to COVID-19, OR
    • who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity).
  • Benefit of treatment with Bebtelovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation.
VIEW THE FULL FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS
INFORMACIÓN EN ESPAÑOL

ADDRESS:

Eastmont Town Center 6955 Foothill Blvd, Suite 67A, Oakland, CA, 94605

BUSINESS HOURS:

Monday – Friday:

8:30am-5:00pm